We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01423084
Recruitment Status : Completed
First Posted : August 25, 2011
Results First Posted : February 20, 2015
Last Update Posted : February 20, 2015
Sponsor:
Collaborator:
Novartis Vaccines
Information provided by (Responsible Party):
Novartis

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The primary objective of this study is to demonstrate the equivalence of rMenB+OMV NZ lot 1 to rMenB+OMV NZ lot 2 when administered to adolescents, as measured by human serum bactericidal activity (hSBA) geometric mean titers (GMTs) against 3 N. meningitidis serogroup B reference strains (H44/76, 5/99, and NZ98/254) and as measured by ELISA geometric mean concentrations (GMCs) against vaccine antigen 287-953, approximately 30 days after a primary vaccination course of two doses administered one month apart.

Condition or disease Intervention/treatment Phase
Meningococcal Disease Meningococcal Meningitis Biological: Serogroup B meningococcal vaccine Phase 3

Detailed Description:
Novartis will consider this study a success if, at one month following the second vaccination, the two-sided 95% CI of the ratio of the hSBA GMTs for each of 3 serogroup B reference strains (H44/76, 5/99, and NZ98/254) and the two-sided 95% CI of the ratio of the ELISA GMCs against vaccine antigen 287-953 are contained within the interval (0.5, 2.0).
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 344 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 3, Randomized, Comparative, Multicenter Observer-Blind Study Evaluating the Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years
Study Start Date : August 2011
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vaccines

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: MenB Lot 1
MenB vaccine Lot 1: 2 doses administered 1 month apart
 Biological: Serogroup B meningococcal vaccine

All subjects will receive two rMenB+OMV NZ vaccinations one month apart and will be followed for a total of 2 months. Subjects will be randomized to 1 of 2 treatment arms to receive either two doses of rMenB+OMV NZ vaccine Lot 1 or two doses of rMenB+OMV NZ Lot 2.

A total of 2 blood samples will be collected (at the first vaccination and 1 month after the 2nd vaccination). An additional blood draw will be collected in a subset of approximately 160 subjects (approximately 80 subjects in Group 1 and approximately 80 subjects in Group 2) at 2 weeks after the second vaccination
Active Comparator: MenB Lot 2
MenB vaccine Lot 2: 2 doses administered 1 month apart
 Biological: Serogroup B meningococcal vaccine

All subjects will receive two rMenB+OMV NZ vaccinations one month apart and will be followed for a total of 2 months. Subjects will be randomized to 1 of 2 treatment arms to receive either two doses of rMenB+OMV NZ vaccine Lot 1 or two doses of rMenB+OMV NZ Lot 2.

A total of 2 blood samples will be collected (at the first vaccination and 1 month after the 2nd vaccination). An additional blood draw will be collected in a subset of approximately 160 subjects (approximately 80 subjects in Group 1 and approximately 80 subjects in Group 2) at 2 weeks after the second vaccination


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against 3 Neisseria.Meningitidis (N. Meningitidis) Serogroup B Reference Strains. [ Time Frame: One month after the second vaccination (day 61) ]
    Consistency of the immune response of the two lots of rMenB+OMV NZ will be assessed at one month after the second vaccination based on the ratio of the vaccine lot hSBA GMTs for each of three serogroup B reference strains (H44/76, 5/99, and NZ98/254) and based on the ratio of Enzyme-linked Immunosorbent Assay (ELISA) GMCs for vaccine antigen 287-953. The equivalence interval will be (0.5, 2.0).

  2. ELISA Geometric Mean Concentration (GMCs) Against Vaccine Antigen 287-953 [ Time Frame: One month after the second vaccination (day 61) ]
    The immune response of two different lots of rMenB+OMV NZ is evaluated in terms of ELISA GMCs against vaccine antigen 287-953.


Secondary Outcome Measures :
  1. Percentage of Subjects in Each Lot With hSBA ≥ 1:5 [ Time Frame: One month after the second vaccination (day 61) ]
    The percentage of subjects in each lot with hSBA ≥ 1:5 at one month after the second vaccination for each of the three reference strains (H44/76, 5/99, and NZ98/254) for each vaccine group

  2. Geometric Mean Ratio (GMR) of GMTs Against Each of N. Meningitidis Serogroup B Reference Strains. [ Time Frame: One month after the second vaccination (day 61) ]
    The immune response of two different lots of rMenB+OMV NZ against each of N. meningitidis serogroup B test strains is evaluated in terms of GMR between GMTs (1month after the second vaccination vs baseline).

  3. Geometric Mean Ratio (GMR) of ELISA Geometric Mean Concentration (GMCs) Against Antigen 287-953 [ Time Frame: One month after the second vaccination (day 61) ]
    The immune response of two different lots of rMenB+OMV NZ against antigen 287-953 is evaluated in terms of GMRs between ELISA GMCs (day 61 vs baseline).

  4. hSBA GMT Against 3 N. Meningitidis Serogroup B Reference Strains at Day 45. [ Time Frame: Two weeks after the second vaccination (day 45) ]
    The immunogenicity of two different lots of rMenB+OMV NZ is evaluated in terms of hSBA GMT against 3 N. Meningitidis serogroup B reference strains at two weeks after last vaccination.

  5. GMRs of GMT Against 3 N. Meningitidis Serogroup B Reference Strains at Day 45. [ Time Frame: Two weeks after the second vaccination (day 45) ]

    The immunogenicity of two different lots of rMenB+OMV NZ is evaluated in terms of GMRs of GMT against 3 N.

    meningitidis serogroup B reference strains at two weeks after last vaccination.


  6. Percentage of Subjects With hSBA ≥1:5 Against Each of N. Meningitidis Serogroup B Reference Strains at Day 45. [ Time Frame: Two weeks after the second vaccination (day 45) ]
    The immune response of two different lots of rMenB+OMV NZ against each of N. Meningitidis serogroup B reference strains is evaluated in terms of percentages of subjects with hSBA ≥1:5 two weeks after the last vaccination.

  7. ELISA GMCs Against Vaccine Antigen 287-953 at Day 45. [ Time Frame: Two weeks after the second vaccination (day 45) ]
    The immune response of two different lots of rMenB+OMV NZ is evaluated in terms of ELISA GMCs against vaccine antigen 287-953.

  8. GMR of ELISA GMCs Against Antigen 287-953 at Day 45. [ Time Frame: Two weeks after the second vaccination (day 45) ]
    The immune response of two different lots of rMenB+OMV NZ against antigen 287-953 is evaluated in terms of GMRs between ELISA GMCs (day 45 vs baseline).

  9. Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) [ Time Frame: From day 1 to day 7 after any vaccination ]
    Number of subjects reporting solicited local and systemic Adverse Events and other indicators of reactogenicity after any vaccination.

  10. Number of Subjects Reporting Unsolicited AEs [ Time Frame: From day 1 to day 7 after any vaccination. ]
    Number of subjects reporting any Unsolicited AEs after any vaccination.

  11. Number of Subjects Reporting SAEs and AE Leading to Withdrawal [ Time Frame: Throughout the study period. ]
    Number of subjects reporting any Serious AEs (SAEs), medically attended AEs and AEs that result in a subject's withdrawal from the study after any vaccination.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   11 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male and female subjects (11-17 years of age inclusive) who have given their written assent and whose parents or legal guardians have given written informed consent at the time of enrollment
  • who are available for all the visits scheduled in the study (i.e., not planning to leave the area before the end of the study period)
  • in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator.

Exclusion Criteria:

  • History of any serogroup B meningococcal vaccination
  • Current or previous, confirmed or suspected disease caused by N. meningitidis
  • Exposure to an individual with any laboratory confirmed N. meningitidis infection within 60 days of enrollment
  • Significant acute or chronic infection within the previous 7 days or fever (defined as axillary temperature ≥ 38.0 °C) within the previous day
  • Antibiotic use within 3 days (72 hours) prior to enrollment
  • Pregnancy or nursing (breastfeeding) mothers
  • Females of childbearing age who have not used or do not plan to use acceptable birth control measures, for the 2 months duration of the study. If sexually active the subject must have been using one of the accepted birth control methods for at least 30 days prior to study entry
  • Any serious chronic or progressive disease, Known or suspected impairment/alteration of the immune system
  • Receipt of blood, blood products and/or plasma derivatives, or a parenteral immunoglobulin preparation within the previous 90 days
  • History of severe allergic reactions after previous vaccinations or hypersensitivity to any vaccine component
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01423084


Locations
Layout table for location information
Australia, Queensland
Royal Children's Hospital
Herston, Queensland, Australia, 4029
AusTrials Pty Ltd-Suites 6, 10 & 11, Peninsula Specialist Centre
Kippa-Ring, Queensland, Australia, 4021
AusTrials Pty Ltd-Suite 5, Level 1, 14 Primrose Street
Sherwood, Queensland, Australia, 4075
Australia, South Australia
Women's and Children's Hospital, 72 King William Road
North Adelaide, South Australia, Australia, 5006
Australia, Victoria
Murdoch Children's Research Institute-Level 5, 207 Bouverie St-University of Melbourne
Melbourne, Victoria, Australia, 3010
Australia, Western Australia
Telethon Institute for Child Heath Research-cnr
Hamilton Street and Roberts Road-Subiaco, Western Australia, Australia, 6008
Canada, British Columbia
TASC Research Services, 1-15243 91st Avenue
Surrey, British Columbia, Canada, V3R 8P8
Canada, Nova Scotia
Colchester Regional Hospital Colchester Research Group, 68 Robie Street
Truro, Nova Scotia, Canada, B2N 1L2
Canada, Ontario
Albion Finch Medical Centre, 1620 Albion Road, Suite 106
Etobicoke, Ontario, Canada, M9V 4B4
Medicor Research Inc, 359 Riverside, Suite 200
Sudbury, Ontario, Canada, P3E 1H5
SKDS Research Inc, 221-679 Davis Dr.Newmarket
Toronto, Ontario, Canada, L3Y 5G8
Dr. Hartley Garfield Medicine Professional Corporation, 790 Bay Street, Suite 540
Toronto, Ontario, Canada, M5G 1N8
Devonshire Clinical Research INC, 423 Devonshire Ave., Suite 301
Woodstock, Ontario, Canada, N4S 5P5
Sponsors and Collaborators
Novartis
Novartis Vaccines
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Novartis
ClinicalTrials.gov Identifier: NCT01423084    
Other Study ID Numbers: V72_41
First Posted: August 25, 2011    Key Record Dates
Results First Posted: February 20, 2015
Last Update Posted: February 20, 2015
Last Verified: February 2015
Keywords provided by Novartis:
Meningococcal Meningitis
prevention, vaccination
adolescents
Additional relevant MeSH terms:
Layout table for MeSH terms
Meningococcal Infections
Meningitis, Meningococcal
Meningitis
Central Nervous System Diseases
Nervous System Diseases
Neisseriaceae Infections
Gram-Negative Bacterial Infections
 Bacterial Infections
Bacterial Infections and Mycoses
Infections
Meningitis, Bacterial
Central Nervous System Bacterial Infections
Central Nervous System Infections